CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 31 enrolled
Drug / intervention
Active tDCS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05092516
NCT05092516N/AActive
CompareCT.gov

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Cognitive Post-acute Sequelae of COVID-19 (PASC)

Massachusetts General Hospital·interventional·Posted Oct 25, 2021·Updated Apr 30, 2026

In Brief

A clinical study evaluating Active tDCS and Sham tDCS for Dysexecutive Syndrome and Post-Acute Sequelae of COVID-19. Active but no longer recruiting, targeting 31 participants across 1 site.

Detailed Summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysexecutive Syndrome, Post-Acute Sequelae of COVID-19
CountriesUnited States
Collaborators--

Timeline

N/AActiveOverdue
20222023202420252026
First PostedOct 25, 2021
Enrollment StartJun 7, 2022
Primary CompletionMar 13, 2025
Study CompletionJun 15, 2026
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.7 years ago

Interventions

Active tDCSdevice

2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.

Sham tDCSdevice

Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.